Once again the MMJ Phytotech Ltd (ASX: MMJ) share price has been one of the biggest movers on the market this morning.
In early trade the pot stock's share price has risen a massive 13%, bringing its month-to-date return to a staggering 169%.
Today's announcement reveals that MMJ Phytotech's partner HL Pharma Pty Ltd has received its medicinal cannabis import licence from the Australian Department of Health. This is a significant step towards supplying the Australian medicinal cannabis market.
The next step for the company will be to seek approval to supply its cannabidiol capsules to the Australian market via its Swiss subsidiary Satispharm.
This looks set to make it one of the first medicinal cannabis products available on the Australian market, giving the company a first mover advantage.
Should you invest?
Whilst I think the medical cannabis market could prove to be incredibly lucrative in the future, I think the share prices of MMJ Phytotech, Auscann Group Holdings Ltd (ASX: AC8), and Zelda Therapeutics Ltd (ASX: ZLD) may have run a little ahead of themselves right now.
Because of this I am a touch concerned that there could be a spot of profit taking in the near future that drives their share prices sharply lower.
For this reason I'm going to watch this exciting industry from the safety of the sidelines and focus on other areas of the market.
For example, healthcare shares such as Mayne Pharma Group Ltd (ASX: MYX) and Nanosonics Ltd. (ASX: NAN) could be worth a closer look today in my opinion.
